YMAB
Y-mAbs Therapeutics
YMAB
YMAB
Delisted
YMAB was delisted on the 15th of September, 2025.
112 hedge funds and large institutions have $225M invested in Y-mAbs Therapeutics in 2024 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 31 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
7% more funds holding
Funds holding: 105 → 112 (+7)
6.55% more ownership
Funds ownership: 57.75% → 64.3% (+6.5%)
33% less capital invested
Capital invested by funds: $339M → $225M (-$113M)
Holders
112
Holding in Top 10
2
Calls
$50K
Puts
$8K
Top Buyers
| 1 | +$4.48M | |
| 2 | +$1.57M | |
| 3 | +$1.17M | |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$1.07M |
| 5 |
State Street
Boston,
Massachusetts
|
+$819K |
Top Sellers
| 1 | -$8.03M | |
| 2 | -$1.39M | |
| 3 | -$1.35M | |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$1.24M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$743K |